모르키오 증후군 치료 시장 규모, 점유율, 성장 분석 : 치료법별, 질환 유형별, 유통경로별, 지역별 - 업계 예측(2026-2033년)

Global Morquio Syndrome Treatment Market size was valued at USD 164.62 Million in 2024 and is poised to grow from USD 174.17 Million in 2025 to USD 273.44 Million by 2033, growing at a CAGR of 5.8% during the forecast period (2026-2033).

Morquio syndrome, an uncommon inherited metabolic disorder affecting skeletal development, falls under the mucopolysaccharidosis (MPS) category. The growing incidence of this condition globally is a significant driver of the Morquio syndrome treatment market. Increased support from government and corporate sectors, along with heightened demand for targeted therapies, is further fueling market growth. The landscape is characterized by rising mergers and partnerships among manufacturers aimed at enhancing treatment options. Additionally, factors such as growing healthcare expenditures, evolving lifestyles, technological advancements, and the prevalence of genetic disorders are positively influencing the market. However, challenges such as inadequate reimbursement policies in cost-sensitive markets, high production costs, and limited treatment awareness may hinder market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Morquio Syndrome Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Morquio Syndrome Treatment Market Segments Analysis

Global Morquio Syndrome Treatment Market is segmented by Treatment, Disease Type, Distribution Channel and region. Based on Treatment, the market is segmented into Enzyme Replacement Therapy and Others. Based on Disease Type, the market is segmented into Morquio A and Morquio B. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Morquio Syndrome Treatment Market

The Global Morquio Syndrome Treatment market is poised for significant growth, driven by an upsurge in research and development of new therapies targeting this rare disease. With numerous products advancing through various stages of development, there is heightened optimism surrounding their potential regulatory approval, particularly following the recent success of elosulfase alfa (VIMIZIM). As companies increasingly prioritize rare disease treatments, the influx of innovative medications in the pipeline promises to fulfill unmet medical needs and enhance patient care. This evolving landscape suggests a robust market trajectory, fueled by advancements in clinical trials and therapeutic options for those affected by Morquio syndrome.

Restraints in the Global Morquio Syndrome Treatment Market

The Global Morquio Syndrome Treatment market faces several restraints that may hinder its growth. A significant challenge is the high cost associated with treatment options, with estimates suggesting that therapies like VIMIZIM could amount to approximately $380,000 per patient each year. Additionally, a lack of awareness and understanding of Morquio syndrome in emerging markets poses a barrier to treatment adoption. Furthermore, clinical and regulatory hurdles add complexity to the development and accessibility of effective therapies, which could further limit the market's potential expansion. Collectively, these factors contribute to a challenging environment for the Morquio syndrome treatment sector.

Market Trends of the Global Morquio Syndrome Treatment Market

The Global Morquio Syndrome Treatment market is experiencing a notable upward trend, driven by intensified research and development efforts from key industry players and growing regulatory approvals. Major pharmaceutical companies are increasingly including Morquio syndrome in their clinical pipelines, with ongoing Phase 3 trials and innovative therapeutic approaches under investigation. This surge in activity reflects a broader awareness of the condition, leading to heightened public interest and demand for effective treatments. As a result, the market is poised for robust growth, propelled by advancements in scientific understanding, technological innovation, and improved access to treatment options for affected individuals.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Studies

Global Morquio Syndrome Treatment Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Enzyme Replacement Therapy
• Others

Global Morquio Syndrome Treatment Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Morquio A
• Morquio B

Global Morquio Syndrome Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Morquio Syndrome Treatment Market Size & CAGR (2026-2033)

• North America (Treatment, Disease Type, Distribution Channel)
  • US
  • Canada
• Europe (Treatment, Disease Type, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Disease Type, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Disease Type, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Disease Type, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• BioMarin Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genzyme Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shire plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JCR Pharmaceuticals Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ArmaGen, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GREEN CROSS CORP (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Concert Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Actelion Pharmaceuticals Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ultragenyx Pharmaceutical Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Enzyvant Therapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations